Advice
in the absence of a submission from the holder of the marketing authorisation:
lenalidomide (Revlimid®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of adult patients with relapsed or refractory mantle cell lymphoma.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice109KB (PDF)
Medicine details
- Medicine name:
- lenalidomide (Revlimid)
- SMC ID:
- 1211/16
- Indication:
- Treatment of adult patients with relapsed or refractory mantle cell lymphoma.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 November 2016